Area of research
Molecular Biology · Oncology
Research interest
Research interests include Melanoma and MAPK Pathways, Cutaneous Melanoma Detection and Management, Brain Metastases and Treatment, and Cancer Immunotherapy and Biomarkers.
RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma.
Data from RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma
Rare Melanomas: An Area of Urgent Research and Clinical Need.
A Multi-Step Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma.
Figure S5 from RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma
Figure S6 from RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma
Figure S10 from RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma
Figure S1 from RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma
Figure S11 from RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma
Figure S4 from RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma
Figure S2 from RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma
Table S1 from RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma
Figure S3 from RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma
Figure S9 from RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma
Figure S7 from RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma
Figure S8 from RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma
Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors.
Identification of anti-TIM-3 based checkpoint inhibitor combinations with activity in immunotherapy refractory melanoma models.
Legends to Supplementary Data from Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing <i>NRAS</i>-Mutant Melanoma to MEK Inhibitors
GDF15 reprograms the microenvironment to drive the development of uveal melanoma liver metastases
Meeting Report From the 2023 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Philadelphia, PA, November 2023.
Data from Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing <i>NRAS</i>-Mutant Melanoma to MEK Inhibitors
Figure S2 from Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing <i>NRAS</i>-Mutant Melanoma to MEK Inhibitors
Figure S3 from Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing <i>NRAS</i>-Mutant Melanoma to MEK Inhibitors
Figure S6 from Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing <i>NRAS</i>-Mutant Melanoma to MEK Inhibitors
Table S1 from Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing <i>NRAS</i>-Mutant Melanoma to MEK Inhibitors
Figure S1 from Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing <i>NRAS</i>-Mutant Melanoma to MEK Inhibitors
Figure S7 from Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing <i>NRAS</i>-Mutant Melanoma to MEK Inhibitors
Figure S5 from Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing <i>NRAS</i>-Mutant Melanoma to MEK Inhibitors
Figure S4 from Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing <i>NRAS</i>-Mutant Melanoma to MEK Inhibitors